IRIS
Paoletti, Giovanni
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.262
AS - Asia 2.811
EU - Europa 1.023
SA - Sud America 515
Continente sconosciuto - Info sul continente non disponibili 148
AF - Africa 110
OC - Oceania 24
Totale 8.893
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.126
SG - Singapore 1.658
CN - Cina 504
BR - Brasile 424
IT - Italia 402
VN - Vietnam 248
FI - Finlandia 96
IE - Irlanda 89
HK - Hong Kong 85
GB - Regno Unito 78
DE - Germania 76
IN - India 65
CA - Canada 64
FR - Francia 57
NG - Nigeria 55
NL - Olanda 42
AR - Argentina 38
BD - Bangladesh 37
RU - Federazione Russa 30
MX - Messico 28
ID - Indonesia 23
ES - Italia 22
SE - Svezia 22
AU - Australia 21
TR - Turchia 21
IQ - Iraq 20
JP - Giappone 20
PK - Pakistan 20
ZA - Sudafrica 20
CZ - Repubblica Ceca 16
AT - Austria 15
EC - Ecuador 14
PL - Polonia 13
UA - Ucraina 13
CL - Cile 12
EG - Egitto 12
MY - Malesia 12
SA - Arabia Saudita 12
BE - Belgio 11
CO - Colombia 9
IL - Israele 9
PH - Filippine 8
CR - Costa Rica 7
LT - Lituania 7
NP - Nepal 7
VE - Venezuela 7
JM - Giamaica 6
KE - Kenya 6
TW - Taiwan 6
UZ - Uzbekistan 6
AL - Albania 5
HN - Honduras 5
KR - Corea 5
SN - Senegal 5
AE - Emirati Arabi Uniti 4
DZ - Algeria 4
GT - Guatemala 4
IR - Iran 4
JO - Giordania 4
KG - Kirghizistan 4
KZ - Kazakistan 4
LB - Libano 4
LV - Lettonia 4
MA - Marocco 4
NI - Nicaragua 4
PE - Perù 4
PT - Portogallo 4
PY - Paraguay 4
SV - El Salvador 4
TH - Thailandia 4
BG - Bulgaria 3
CH - Svizzera 3
TN - Tunisia 3
AZ - Azerbaigian 2
BB - Barbados 2
BH - Bahrain 2
DO - Repubblica Dominicana 2
EE - Estonia 2
HR - Croazia 2
HU - Ungheria 2
NZ - Nuova Zelanda 2
PA - Panama 2
PR - Porto Rico 2
PS - Palestinian Territory 2
RO - Romania 2
SY - Repubblica araba siriana 2
TT - Trinidad e Tobago 2
UY - Uruguay 2
XK - ???statistics.table.value.countryCode.XK??? 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BA - Bosnia-Erzegovina 1
BM - Bermuda 1
BO - Bolivia 1
BY - Bielorussia 1
BZ - Belize 1
CY - Cipro 1
DK - Danimarca 1
ET - Etiopia 1
FJ - Figi 1
GD - Grenada 1
Totale 8.735
Salva come PNG Salva come JPEG
Città #
Singapore 689
San Jose 416
Ashburn 365
The Dalles 242
Chandler 220
Shanghai 188
Council Bluffs 171
Dallas 159
New York 153
Wilmington 140
Santa Clara 121
Los Angeles 116
Beijing 112
Boardman 95
Helsinki 95
Dublin 88
Milan 85
Ho Chi Minh City 81
Hong Kong 78
San Mateo 63
Hanoi 59
Benin City 54
Buffalo 50
Phoenix 49
Princeton 49
Rome 44
Lawrence 33
Paris 30
Ann Arbor 29
São Paulo 29
Seattle 26
Naples 25
Leawood 24
Orem 22
Amsterdam 20
London 20
Charlotte 18
Chicago 18
Philadelphia 17
Atlanta 16
Brooklyn 16
Montreal 15
Toronto 15
Belo Horizonte 14
Fairfield 14
Boston 13
Curitiba 13
Frankfurt am Main 13
Houston 13
Miami 13
Tokyo 13
Da Nang 12
San Francisco 12
Warsaw 12
Brasília 11
Mumbai 11
Pune 11
Woodbridge 11
Assago 10
Genoa 10
Newark 10
Queens 10
Brno 9
Cairo 9
Chennai 9
Denver 9
Falkenstein 9
Figino 9
Haiphong 9
Mexico City 9
Munich 9
Parma 9
Rio de Janeiro 9
Stockholm 9
Tampa 9
Abbeville 8
Bar Harbor 8
Corigliano Calabro 8
Fayetteville 8
Hải Dương 8
Johannesburg 8
Porto Alegre 8
Turin 8
Campinas 7
Columbus 7
Guarulhos 7
Hyderabad 7
Kuala Lumpur 7
Orlando 7
Secaucus 7
Sydney 7
Vienna 7
Ambivere 6
Florence 6
Guayaquil 6
Jumet 6
Moscow 6
Nuremberg 6
Pasadena 6
Spring 6
Totale 4.873
Salva come PNG Salva come JPEG
Nome #
NAPPREB study protocol: A pivotal clinical trial to investigate clinical efficacy and potential response biomarkers to Benralizumab treatment in chronic rhinosinusitis with nasal polyps 176
Very rapid improvement of extended nitric oxide parameters, associated with clinical and functional betterment, in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) treated with Dupilumab 140
Nasal Polyposis Quality of Life (NPQ): Development and Validation of the First Specific Quality of Life Questionnaire for Chronic Rhinosinusitis with Nasal Polyps 140
Allergy clinics in times of the SARS-CoV-2 pandemic: an integrated model 132
An academic allergy unit during COVID-19 pandemic in Italy. 125
Biologic drugs and allergen immunotherapy: potential allies 117
Treatable traits in chronic rhinosinusitis with nasal polyps 111
Alpha1-antitrypsin deficiency and asthma 110
Clinical presentation at the onset of COVID-19 and allergic rhinoconjunctivitis 109
Allergen immunotherapy for respiratory allergy: Quality appraisal of observational comparative effectiveness studies using the REal Life Evidence AssessmeNt Tool. An EAACI methodology committee analysis 109
Allergen immunotherapy and biologics in respiratory allergy: friends or foes? 109
Inappropriate prescription of benzodiazepines in acutely hospitalized older patients 107
New therapeutic approaches with biological drugs for eosinophilic granulomatosis with polyangiitis 106
Asthma from immune pathogenesis to precision medicine 101
Type 2 Inflammation in Eosinophilic Esophagitis: From Pathophysiology to Therapeutic Targets 99
Effect of an educational intervention delivered by pharmacists on adherence to treatment, disease control and lung function in patients with asthma 98
Allergen immunotherapy: The growing role of observational and randomized trial "Real-World Evidence" 97
Extended nitric oxide analysis in patients with chronic rhinosinusitis with nasal polyps, with or without associated asthma 96
Community pharmacist's professional adaptation amid Covid-19 emergency: a national survey on Italian pharmacists 95
Sex-Differences in the Pattern of Comorbidities, Functional Independence, and Mortality in Elderly Inpatients: Evidence from the RePoSI Register 94
Antihypertensive treatment changes and related clinical outcomes in older hospitalized patients 93
New drugs in early-stage clinical trials for allergic rhinitis 93
One year of mepolizumab. Efficacy and safety in real-life in Italy 91
Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial 89
Validation of the Italian version of the Test of Adherence to Inhalers (TAI) 88
Interleukin-5 in the Pathophysiology of Severe Asthma 88
Impact of asthma on bronchiectasis severity and risk of exacerbations 87
Advancing Precision Medicine in Asthma: Evolution of Treatment Outcomes 85
Real-life studies of biologics used in asthma patients: key differences and similarities to trials 84
Clinical features associated with a doctor-diagnosis of bronchiectasis in the Severe Asthma Network in Italy (SANI) registry 84
Airways Type-2 Related Disorders: Multiorgan, Systemic or Syndemic Disease? 83
Allergen immunotherapy in Italy: How, when, and why—A real-world study conducted through a patient association 83
Successful SARS-CoV-2 vaccine allergy risk-management: The experience of a large Italian University Hospital 82
Do the current guidelines for asthma pharmacotherapy encourage over-treatment? 80
Immunostimulants in respiratory diseases: Focus on Pidotimod 80
Validation and Qualification of Biomarkers and Their Translation Into Pathway-Specific Diagnostic Tests 79
The importance of being not significant: blood eosinophils and clinical responses do not correlate in severe asthma patients treated with Mepolizumab in real life. 78
COVID-19 in Severe Asthma Network in Italy (SANI) patients: Clinical features, impact of comorbidities and treatments 78
Gastroesophageal reflux and asthma: when, how, and why 78
Allergic Rhinitis and Its Impact on Asthma (ARIA )‐Guidelines—2024–2025 Revision: Part I—Guidelines on Intranasal Treatments 77
Antibiotic use and associated factors in a large sample of hospitalised older people 77
Critical evaluation of asthma biomarkers in clinical practice 77
Radiological Versus Clinical 1-Year Outcomes of Dupilumab in Refractory CRSwNP: A Real-Life Study 76
Fractional Exhaled Nitric Oxide (FENO) in the management of asthma: a position paper of the Italian Respiratory Society (SIP/IRS) and Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC) 74
Care for Patients with Type-2 Chronic Rhinosinusitis 71
New Onset of Eosinophilic Granulomatosis with Polyangiitis Following mRNA-Based COVID-19 Vaccine 71
Biologics and airway remodeling in severe asthma 71
Polyethylene Glycol and Polysorbate 80 Skin Tests in the Context of an Allergic Risk Assessment for Hypersensitivity Reactions to Anti-SARS-CoV-2 mRNA Vaccines 70
Reply to: Kow CS et al. Are severe asthma patients at higher risk of developing severe outcomes from COVID-19? 70
Impulse oscillometry defined small airway dysfunction in asthmatic patients with normal spirometry: Prevalence, clinical associations, and impact on asthma control 69
Local Allergic Rhinitis: Lights and Shadows of a Mysterious Entity 68
Asthma management, focused on the use of oral corticosteroids: the opinions of Italian asthmatic patients 68
Sex Differences in Severe Asthma: Results From Severe Asthma Network in Italy-SANI 68
Small airway dysfunction and obesity in asthmatic patients: a dangerous liaison? 67
ARIA–Italy managing allergic rhinitis and asthma in a changing world: The role of the Pharmacist 67
Prevalence, characteristics and treatment of chronic pain in elderly patients hospitalized in internal medicine wards 67
Clinical features and outcomes of elderly hospitalised patients with chronic obstructive pulmonary disease, heart failure or both 66
Artificial intelligence processing electronic health records to identify commonalities and comorbidities cluster at Immuno Center Humanitas 66
COPD and biologic treatment: state of the art 66
SANI Clinical Remission definition: a useful tool in Severe Asthma management 65
Oral Immunotherapy with Standardized Peanut Extract: A Game-Changer for Peanut Allergy 65
Mechanisms of Allergen Immunotherapy and Potential Biomarkers for Clinical Evaluation 64
A 300 IR 5-grass pollen sublingual immunotherapy tablet-specific systematic review and meta-analysis confirms its clinical benefits for patients with allergic rhinoconjunctivitis with or without asthma 64
Predictive value of tissue eosinophilia for dupilumab response in chronic rhinosinusitis with nasal polyps: A retrospective monocentric study 61
Comorbid allergic rhinitis and asthma: important clinical considerations 61
Biologics in severe asthma: the role of real-world evidence from registries 61
Use, Abuse, and Misuse of Nasal Medications: Real-Life Survey on Community Pharmacist's Perceptions 60
Vocal biomarkers correlate with FEV1 variations during methacholine challenge 60
Intranasal corticosteroid and antihistamine combinations in the treatment of allergic rhinitis: the role of the novel formulation olopatadine/mometasone furoate 58
Clinical remission in severe asthma: lights and shadows on an ambitious goal 57
Oral Corticosteroid Abuse and Self-Prescription in Italy: A Perspective from Community Pharmacists and Sales Reports before and during the COVID-19 Era 56
Sleep quality burden in chronic rhinosinusitis with nasal polyps and its modulation by Dupilumab 54
Real-world effectiveness of mepolizumab in asthma: a systematic review and meta-analysis 53
Mortality rate and risk factors for gastrointestinal bleeding in elderly patients 53
Hospital Care of Older Patients With COPD: Adherence to International Guidelines for Use of Inhaled Bronchodilators and Corticosteroids 53
Desensitization Protocols for Anti-SARS-CoV-2 Vaccines in Patients with High Risk of Allergic Reactions 53
Prevalence of familial link in patients affected by chronic rhinosinusitis with nasal polyposis 52
Polypharmacy in older people: lessons from 10 years of experience with the REPOSI register 52
Asthma severity: the patient’s point of view 52
Diagnostic delay and misdiagnosis in eosinophilic oesophagitis 52
Drug–drug interactions involving CYP3A4 and p-glycoprotein in hospitalized elderly patients 52
Assessing Nasal Obstruction Improvement in Dupilumab-Treated Patients With Active Anterior Rhinomanometry: A Preliminary Study 51
The Prevalence of Immediate Hypersensitivity Reactions to the BNT162b2 mRNA Vaccine against SARS-CoV-2: Data from the Vaccination Campaign in a Large Academic Hospital 51
Comparability of Asthma Control Test (ACT) scores between self and physician administered test 51
Current treatment strategies for seasonal allergic rhinitis: where are we heading? 50
Prediction of Clinical Response to Dupilumab for CRSwNP Based on the Amsterdam Classification of Completeness of Endoscopic Sinus Surgery (ACCESS) Score 50
Real-world data: A relevant component in the framework of scientific evidence 50
Exhaled nitric oxide in asthma: from diagnosis to management 49
Mast Cells in Upper and Lower Airway Diseases: Sentinels in the Front Line 49
Vaping effects on asthma: results from a web survey and clinical investigation 49
Statistical advice provided by ChatGPT regarding an accepted article in Allergy 48
Pattern of comorbidities and 1-year mortality in elderly patients with COPD hospitalized in internal medicine wards: data from the RePoSI Registry 48
Allergen immunotherapy: effective on lung function? 47
Prevalence of use and appropriateness of antidepressants prescription in acutely hospitalized elderly patients 47
Hypersensitivity Reactions to Iodinated Contrast Media: A Narrative Review of Current Evidence and Clinical Challenges 47
Editorial comment on “Environmental influences on childhood asthma: Climate change” 46
Depemokimab in chronic rhinosinusitis with nasal polyps: A turning point or a missed opportunity? 46
New evidence in food allergies treatment 46
Cross-Cultural Validation of the Short Version of the Questionnaire of Olfactory Disorders-Negative Statements into Italian: Towards Personalized Patient Care 46
Outcomes of Non‐Mucosa Sparing Endoscopic Sinus Surgery (Partial Reboot) in Refractory Chronic Rhinosinusitis with Nasal Polyposis: An Academic Hospital Experience 45
Totale 7.454
Salva come PNG Salva come JPEG
Categoria #
all - tutte 51.458
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 51.458
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022175 0 0 0 41 0 0 4 29 8 22 59 12
2022/2023618 80 48 50 75 65 40 0 41 112 46 43 18
2023/2024868 76 68 164 37 34 85 72 44 21 36 72 159
2024/20251.434 69 25 28 30 38 137 77 108 254 302 161 205
2025/20264.054 484 231 229 398 209 177 1.015 226 220 281 224 360
2026/20271.459 272 289 708 190 0 0 0 0 0 0 0 0
Totale 8.893